Literature DB >> 24256572

Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre.

Xingshun Qi1, Wengang Guo, Chuangye He, Wei Zhang, Feifei Wu, Zhanxin Yin, Ming Bai, Jing Niu, Zhiping Yang, Daiming Fan, Guohong Han.   

Abstract

BACKGROUND & AIMS: In Western countries, transjugular intrahepatic portosytemic shunt (TIPS) is widely applied for the treatment of Budd-Chiari syndrome (BCS). However, the outcome of Chinese BCS patients treated with TIPS is extremely limited. Furthermore, the timing of conversion from percutaneous recanalization to TIPS remains uncertain.
METHODS: All consecutive BCS patients treated with TIPS between December 2004 and June 2012 were included. Patients were classified as the early and converted TIPS groups. Indications, TIPS-related complications, post-TIPS hepatic encephalopathy, shunt dysfunction and death were reported.
RESULTS: Of 51 patients included, 39 underwent percutaneous recanalization for 1024 days (0-4574) before TIPS. Early TIPS group (n = 19) has a shorter history of BCS and a lower proportion of prior percutaneous recanalization than converted TIPS group (n = 32). Main indications were diffuse obstruction of three HVs (n = 12), liver failure (n = 2), liver function deterioration (n = 8), refractory ascites (n = 10) and variceal bleeding (n = 19). Procedure-related intraperitoneal bleeding was reversible in three patients. The cumulative 1-year rate of being free of first episode of post-TIPS hepatic encephalopathy and shunt dysfunction was 78.38 and 61.69% respectively. The cumulative 1-, 2-, and 3-year survival rates were 83.82, 81.20 and 76.93% respectively. BCS-TIPS score, but not Child-Pugh, MELD, Clichy or Rotterdam score, could predict the survival. Age, total bilirubin and inferior vena cava thrombosis were also significantly associated with overall survival. Survival was similar between early and converted TIPS groups.
CONCLUSIONS: TIPS can achieve an excellent survival in Chinese patients in whom percutaneous recanalization is ineffective or inappropriate. BCS-TIPS score could effectively predict these patients' survival.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Budd-Chiari syndrome; prognosis; transjugular intrahepatic portosystemic shunt; treatment

Mesh:

Year:  2013        PMID: 24256572     DOI: 10.1111/liv.12355

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  18 in total

1.  Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome.

Authors:  Zhong-Ke Chen; Jing Fan; Chi Cao; Yu Li
Journal:  Radiol Med       Date:  2018-05-31       Impact factor: 3.469

2.  Recurrent Budd-Chiari Syndrome Presenting with Lower Limb Ulcers.

Authors:  Xingshun Qi; Feifei Wu; Daiming Fan; Guohong Han
Journal:  J Clin Exp Hepatol       Date:  2015-04-30

Review 3.  Selection of treatment modalities for Budd-Chiari Syndrome in China: a preliminary survey of published literature.

Authors:  Xing-Shun Qi; Wei-Rong Ren; Dai-Ming Fan; Guo-Hong Han
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 4.  Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review.

Authors:  Xing-Shun Qi; Ming Bai; Zhi-Ping Yang; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 5.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

6.  Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist's Perspective.

Authors:  Andrea Mancuso
Journal:  J Transl Int Med       Date:  2017-12-29

7.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

8.  Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.

Authors:  Yan-Feng Cui; Yu-Fei Fu; De-Chun Li; Hao Xu
Journal:  Hepatol Int       Date:  2015-10-23       Impact factor: 6.047

9.  Imbalance of pro- vs. anti-coagulation factors in Chinese patients with Budd-Chiari syndrome and non-cirrhotic portal vein thrombosis.

Authors:  Hui Chen; Lei Liu; Xingshun Qi; Chuangye He; Zhanxin Yin; Feifei Wu; Daiming Fan; Guohong Han
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

10.  Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: A single-center study.

Authors:  Mohammad Sakr; Sara M Abdelhakam; Soheir A Elsayed; Enas H Allam; Amir M Farid; Waleed Abdelmoaty; Azza M Hassan; Mohamed Shaker; Mohamed El-Gharib; Ahmed Eldorry
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.